Company news
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news
Every Sarepta Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
September 8, 2026
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
August 5, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
July 30, 2026
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
July 27, 2026
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
July 22, 2026
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 1, 2026
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2026
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
May 6, 2026
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
April 22, 2026
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 25, 2026
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 24, 2026
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
March 19, 2026
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
March 16, 2026
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
February 27, 2026
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
February 26, 2026
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
February 25, 2026
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
February 24, 2026
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
February 11, 2026
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
February 4, 2026
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
January 26, 2026
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
January 23, 2026
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
January 12, 2026
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
January 7, 2026
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2025
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
December 11, 2025
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
November 25, 2025
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
November 24, 2025
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
November 14, 2025
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
November 3, 2025
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
October 27, 2025
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
October 23, 2025
Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
October 21, 2025
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
October 3, 2025
MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
September 15, 2025
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
September 5, 2025
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
August 26, 2025
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
August 21, 2025
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
August 13, 2025
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
August 6, 2025
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
July 31, 2025
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
July 28, 2025
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
July 25, 2025
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
July 25, 2025
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
July 23, 2025
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
July 21, 2025
Sarepta Therapeutics Provides Statement on ELEVIDYS
July 18, 2025